Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20109405 | 0.86 | HPGD (0.40) | HPGDSMN1; SMN2PKMGAAPOLB | |
| SCHEMBL20113584 | 0.85 | PTGS2 (0.36) | HPGDSMN1; SMN2PKMGAATLR2 | |
| SCHEMBL20100738 | 0.81 | SMN1; SMN2 (0.34) | HPGDSMN1; SMN2GAALMNAALDH1A1 | |
| SCHEMBL20100740 | 0.78 | TLR2 (0.39) | HPGDSMN1; SMN2PKMGAATLR2 | |
| SCHEMBL25602351 | 0.77 | HPGD (0.50) | HPGDSMN1; SMN2CYP2D6CYP2C19EPHX2 | |
| SCHEMBL20104862 | 0.75 | HPGD (0.46) | HPGDSMN1; SMN2PKMGAATLR2 | |
| SCHEMBL20104858 | 0.74 | PKM (0.41) | HPGDSMN1; SMN2PKMGAAPOLB | |
| SCHEMBL20104867 | 0.73 | HPGD (0.39) | HPGDSMN1; SMN2PKMGAAPOLB | |
| SCHEMBL20100773 | 0.73 | HPGD (0.38) | HPGDSMN1; SMN2PKMGAATLR2 | |
| SCHEMBL24636691 | 0.72 | HPGD (0.46) | HPGDSMN1; SMN2TLR2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118676-A1 | NITRIC OXIDE DONATING DERIVATIVES OF LATANOPROST FREE ACID | NICOX S.A. (FR) | 2018-05-03 | — | — | US | disclosed |
| US-20180118677-A1 | NITRIC OXIDE DONATING DERIVATIVES OF FLUPROSTENOL | NICOX S.A. (FR) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118677-A1 | NITRIC OXIDE DONATING DERIVATIVES OF FLUPROSTENOL | PTGIS, NOS2, PTGIR | HPGD 7/4885SMN1; SMN2 4789/4885PKM 2493/4885 |
| US-20180118676-A1 | NITRIC OXIDE DONATING DERIVATIVES OF LATANOPROST FREE ACID | PTGIS, NOS2, NOS1 | HPGD 10/4885SMN1; SMN2 4557/4885PKM 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.